Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

BC43

Inter-amer 30 (BC43)

Inter-amer 30

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:BC43

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
13/11/2002	15h09	UK Regulatory	Rebecca O. Kendall Announces Retirement; Robert A. Armitage Promoted to Lilly Senior Vice President, General Counsel	LSE:BC43	Inter-amer 30
09/11/2002	10h30	UK Regulatory	Eli Lilly and Company	LSE:BC43	Inter-amer 30
08/11/2002	13h30	UK Regulatory	Lilly Outlines to Wall Street Its Strategy To Realize Its Growth Opportunities and Deliver Superior Earnings Growth Over the Lon	LSE:BC43	Inter-amer 30
08/11/2002	08h19	UK Regulatory	Eli Lilly and Company	LSE:BC43	Inter-amer 30
07/11/2002	19h08	UK Regulatory	Eli Lilly and Company	LSE:BC43	Inter-amer 30
05/11/2002	17h02	UK Regulatory	Eli Lilly and Company	LSE:BC43	Inter-amer 30
01/11/2002	14h47	UK Regulatory	Eli Lilly and Company	LSE:BC43	Inter-amer 30
30/10/2002	16h03	UK Regulatory	Eli Lilly and Company	LSE:BC43	Inter-amer 30
29/10/2002	15h00	UK Regulatory	Cymbalta Data Suggest Rapid and Sustained Response by First Week of Therapy	LSE:BC43	Inter-amer 30
23/10/2002	14h10	UK Regulatory	3rd Quarter Results	LSE:BC43	Inter-amer 30
22/10/2002	09h01	UK Regulatory	Alimta Continues To Show Versatility in Treating Different Cancers	LSE:BC43	Inter-amer 30
21/10/2002	22h15	UK Regulatory	Dividend Declaration	LSE:BC43	Inter-amer 30
18/10/2002	09h00	UK Regulatory	Combining Innovative Therapies for Optimal Cancer Care; Effectiveness of Gemzar-Based Combination Regimens is Topic of Workshop	LSE:BC43	Inter-amer 30
01/10/2002	16h10	UK Regulatory	Newly Published Study Demonstrates Sustained Efficacy of Evista -raloxifene HCl- in Reducing Risk of Spinal Fractures	LSE:BC43	Inter-amer 30
25/09/2002	23h59	UK Regulatory	Lilly Asserts The New England Journal of Medicine ``Sounding Board'' Opinion Article Attempts to Turn Back the Clock on Care of	LSE:BC43	Inter-amer 30
24/09/2002	23h39	UK Regulatory	Re Alliance	LSE:BC43	Inter-amer 30
24/09/2002	02h05	UK Regulatory	Re Alliance	LSE:BC43	Inter-amer 30
20/09/2002	15h07	UK Regulatory	Statement re	LSE:BC43	Inter-amer 30
17/09/2002	16h34	UK Regulatory	Lilly Launches World's Largest Severe Sepsis Clinical Trial; 11,000 Patients to be Enrolled in Study of Xigris Use in Patients w	LSE:BC43	Inter-amer 30
16/09/2002	19h02	UK Regulatory	FDA Issues Approvable Letter for Lilly's Cymbalta for Treatment of Depression; From the Makers of Prozac, Cymbalta Will Offer Ne	LSE:BC43	Inter-amer 30
16/09/2002	16h04	UK Regulatory	Miscellaneous	LSE:BC43	Inter-amer 30
03/09/2002	16h08	UK Regulatory	Tadalafil for the Treatment of Erectile Dysfunction Receives Positive Recommendation From the Australian Drug Evaluation Committ	LSE:BC43	Inter-amer 30
26/08/2002	21h11	UK Regulatory	Regulatory Approval	LSE:BC43	Inter-amer 30
26/08/2002	17h44	UK Regulatory	Miscellaneous	LSE:BC43	Inter-amer 30
14/08/2002	21h02	UK Regulatory	Miscellaneous	LSE:BC43	Inter-amer 30
14/08/2002	18h56	UK Regulatory	Miscellaneous	LSE:BC43	Inter-amer 30
14/08/2002	15h29	UK Regulatory	FDA Issues Approvable Letter for Strattera for ADHD; Strattera Would Give Patients, Families and Physicians a New Treatment Opti	LSE:BC43	Inter-amer 30
01/08/2002	09h23	UK Regulatory	Lilly's Xigris Becomes First and Only Medical Product Approved for BIPA Payment in Medicare Patients	LSE:BC43	Inter-amer 30
30/07/2002	16h50	UK Regulatory	Re Alliance	LSE:BC43	Inter-amer 30
25/07/2002	22h03	UK Regulatory	Lilly ICOS LLC	LSE:BC43	Inter-amer 30

Showing the most relevant articles for your search:LSE:BC43

JP Morgan Chase

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen